Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Non-Current Deffered Revenue (2016 - 2018)

VYNE Therapeutics (VYNE) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $6.3 million as the latest value for Q1 2018.

  • For the quarter ending Q1 2018, Non-Current Deffered Revenue changed N/A year-over-year to $6.3 million, compared with a TTM value of $6.3 million through Mar 2018, changed N/A, and an annual FY2017 reading of $6.7 million, down 21.05% over the prior year.
  • Non-Current Deffered Revenue was $6.3 million for Q1 2018 at VYNE Therapeutics, down from $6.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $8.5 million in Q4 2016 and bottomed at $6.3 million in Q1 2018.
  • Average Non-Current Deffered Revenue over 3 years is $7.2 million, with a median of $6.7 million recorded in 2017.
  • Peak annual rise in Non-Current Deffered Revenue hit 21.05% in 2017, while the deepest fall reached 21.05% in 2017.
  • Year by year, Non-Current Deffered Revenue stood at $8.5 million in 2016, then fell by 21.05% to $6.7 million in 2017, then decreased by 6.67% to $6.3 million in 2018.
  • Business Quant data shows Non-Current Deffered Revenue for VYNE at $6.3 million in Q1 2018, $6.7 million in Q4 2017, and $8.5 million in Q4 2016.